Oppenheimer & Co’s Protara Therapeutics TARA Stock Holding History

Oppenheimer & Co’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$664K	Sell	217,631 -20,731	-9%	-$80.7K	0.01%	1095
2026 Q2	$911K	Buy	238,362 +56,797	+31%	+$270K	0.01%	975
2026 Q1	$946K	Sell	181,565 -42,202	-19%	-$250K	0.01%	888
2025 Q4	$1.19M	Buy	223,767 +16,794	+8%	+$93.4K	0.02%	730
2025 Q3	$900K	Sell	206,973 -39,091	-16%	-$127K	0.01%	948
2025 Q2	$746K	Buy	246,064 +59,500	+32%	+$205K	0.01%	984
2025 Q1	$795K	Sell	186,564 -14,862	-7%	-$66.4K	0.01%	899
2024 Q4	$1.06M	Buy	201,426 +22,301	+12%	+$72K	0.02%	755
2024 Q3	$328K	Buy	179,125 +51,944	+41%	+$107K	0.01%	1190
2024 Q2	$265K	Buy	127,181 +117,181	+1,172%	+$343K	﹤0.01%	1240
2024 Q1	$40.1K	Buy	+10,000	New	+$32.3K	﹤0.01%	1418

Other funds holding TARA

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return

Indivisible Partners Clearwater, Florida $2.18B AUM 33.61% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Oppenheimer & Co's TARA Position: Q3 2026 in Review

Oppenheimer & Co reduced its Protara Therapeutics (TARA) stake by 8.7% in Q3 2026, selling an estimated $80.7K and leaving 217,631 shares worth $664K. The position accounts for 0.01% of the portfolio, ranked #1095.

Oppenheimer & Co first reported a position in TARA in Q1 2024 and has held it in 11 quarters since. The position peaked at $1.19M in Q4 2025. 30 funds tracked by Wall St. Rank hold TARA as of Q3 2026.

Oppenheimer & Co held 217,631 shares of Protara Therapeutics worth $664K as of Q3 2026.
Oppenheimer & Co sold 20,731 Protara Therapeutics shares in Q3 2026, an estimated $80.7K.
Protara Therapeutics made up 0.01% of Oppenheimer & Co's portfolio in Q3 2026, its #1095 holding.
Oppenheimer & Co first reported a position in Protara Therapeutics in Q1 2024 and has held it in 11 quarters since.
Oppenheimer & Co's Protara Therapeutics position peaked at $1.19M in Q4 2025.
30 funds tracked by Wall St. Rank held Protara Therapeutics as of Q3 2026.

Based on Oppenheimer & Co's 13F filing for Q3 2026, filed 26 Oct 2026.